Five Prime Therapeutics (FPRX) Tops Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Five Prime Therapeutics (FRPX) PT Raised to $60 at Jefferies
August 5, 2016 9:51 AM EDTJefferies analyst Eun Yang reiterated a Buy rating and raised his price target on Five Prime Therapeutics (NASDAQ: FPRX) to $60.00 (from $41.00) following Q2 results.
Yang commented, "Narrower 2Q net loss on higher revenue; estimated YE16 cash of ~$400M should fund operations into... More
Five Prime Therapeutics (FPRX) Pipeline on Track, Leerink Says; PT to $58
August 5, 2016 8:16 AM EDTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and raised his price target on Five Prime Therapeutics (NASDAQ: FPRX) to $58.00 (from $45.00) following Q2 updated with the pipeline on track.
Schmidt commented, "We updating our estimates to reflect 2Q16 financial results and are maintaining our OP rating on FPRX shares despite the recent... More
